Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
Updates on rucaparib clinical trials in multiple solid tumors and
therapy settings at ASCO Annual Meeting; top-line data from ARIEL3
pivotal study anticipated by end of June
BOULDER, Colo.--(BUSINESS WIRE)--May 23, 2017--
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts
highlighting progress in the rucaparib clinical development program will
be presented at the 2017 American Society of Clinical Oncology (ASCO)
Strong Q1 launch quarter for Rubraca®
(rucaparib) in U.S. with $7M reported in net sales
Clovis notified that ARIEL3 target progression events achieved in
Top-line ARIEL3 data anticipated by end of June
Multiple clinical trials initiated in early 2017, including TRITON2
and TRITON3 in prostate cancer and Roche-sponsored
rucaparib-atezolizumab combination study in gynecologic c...
SALT LAKE CITY, Utah & BOULDER, Colo., April 27, 2017 – Myriad Genetics, Inc. (NASDAQ: MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis' PARP inhibitor, Rubraca. Financial terms of the deal were not disclosed.Under the agreement, Myriad will submit a supplementary premarket approval (sPMA) application under its existing PMA for BRACAnalysis CDx to include Rubraca. The...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.